Gurnet Point Capital, a private equity firm, and Novo, a pharmaceutical holding company, completed the acquisition of Paratek Pharmaceuticals, a commercial-stage biopharmaceutical company, for $462m. “Today’s completion of the acquisition of Paratek by Gurnet Point and Novo represents the beginning of a new chapter in our Company’s history. We look forward to drawing upon the extensive experience of both Gurnet Point and Novo Holdings to provide lifesaving, transformative therapies to patients,” said Evan Loh, Paratek CEO.